Abeona Therapeutics (ABEO) CEO sells 69,832 shares in tax sale

Rhea-AI Filing Summary

Abeona Therapeutics CEO Vishwas Seshadri, who also serves as a director, reported a sale of company common stock. On January 22, 2026, he sold 69,832 shares of Abeona Therapeutics common stock in an open market transaction coded as a sale. The shares were sold at a weighted average price of $5.3309 per share, through multiple trades at prices ranging from $5.33 to $5.38.

According to the filing, this sale was made to cover tax obligations associated with the vesting of restricted stock awards. After the transaction, Seshadri beneficially owned 1,460,408 shares of Abeona Therapeutics common stock directly.

Insider Trade Summary

Net Seller: 69,832 shares ($372,267)

Net Sell 1 txn

Insider Seshadri Vishwas

Role Chief Executive Officer

Sold 69,832 shs ($372K)

Type	Security	Shares	Price	Value
Sale	Common Stock	69,832	$5.3309	$372K

Holdings After Transaction: Common Stock — 1,460,408 shares (Direct)

Footnotes (1)

1. The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.33 to $5.38 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Seshadri Vishwas

(Last) (First) (Middle)

6555 CARNEGIE AVE., 4TH FLOOR

(Street)

CLEVELAND OH 44103

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ABEONA THERAPEUTICS INC. [ ABEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/22/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/22/2026		S(1)		69,832	D	$5.3309(2)	1,460,408	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.33 to $5.38 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

	/s/ Vishwas Seshadri	01/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Abeona Therapeutics (ABEO) report?

The filing reports that CEO and director Vishwas Seshadri sold 69,832 shares of Abeona Therapeutics common stock on January 22, 2026.

Why did the Abeona (ABEO) CEO sell 69,832 shares?

The filing states that the sale was made to cover tax obligations associated with the vesting of restricted stock awards.

At what price were the 69,832 Abeona (ABEO) shares sold?

The shares were sold at a weighted average price of $5.3309 per share, in multiple trades at prices ranging from $5.33 to $5.38.

How many Abeona Therapeutics (ABEO) shares does the CEO own after this sale?

Following the reported transaction, CEO Vishwas Seshadri beneficially owned 1,460,408 shares of Abeona Therapeutics common stock directly.

What type of security did the Abeona (ABEO) insider transaction involve?

The transaction involved common stock of Abeona Therapeutics Inc., reported as a non-derivative security transaction.

Was this Abeona (ABEO) insider transaction made directly by the CEO?

Yes. The Form 4 shows the 69,832-share sale as a direct (D) ownership transaction by CEO and director Vishwas Seshadri.